

Dmitry A Zateyshchikov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/988294/publications.pdf>

Version: 2024-02-01

133
papers

39,032
citations

57681

46
h-index

29333

108
g-index

149
all docs

149
docs citations

149
times ranked

30820
citing authors

#	ARTICLE	IF	CITATIONS
1	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2015, 373, 2117-2128.	13.9	8,841
2	Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2009, 361, 1045-1057.	13.9	6,019
3	Edoxaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2013, 369, 2093-2104.	13.9	4,215
4	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1713-1722.	13.9	4,179
5	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 323-334.	13.9	2,809
6	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
7	Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2006, 354, 1464-1476.	13.9	1,104
8	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 372, 807-816.	6.3	934
9	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	13.9	765
10	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	6.3	651
11	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	13.9	510
12	Rolofylline, an Adenosine A ₁ Receptor Antagonist, in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2010, 363, 1419-1428.	13.9	473
13	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 205-218.	6.3	426
14	Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1006.	3.8	375
15	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 119-129.	1.6	347
16	Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 252.	3.8	270
17	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 1309-1320.	13.9	255
18	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. <i>Lancet, The</i> , 2010, 376, 517-523.	6.3	222

#	ARTICLE	IF	CITATIONS
19	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	1.0	222
20	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	1.2	205
21	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , 2018, 379, 1118-1127.	13.9	205
22	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial. <i>European Heart Journal</i> , 2018, 39, 363-370.	1.0	199
23	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <i>American Heart Journal</i> , 2017, 194, 132-140.	1.2	161
24	The PROTECT Pilot Study: A Randomized, Placebo-Controlled, Dose-Finding Study of the Adenosine A1 Receptor Antagonist Rolofylline in Patients With Acute Heart Failure and Renal Impairment. <i>Journal of Cardiac Failure</i> , 2008, 14, 631-640.	0.7	160
25	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet</i> , The, 2019, 394, 1169-1180.	6.3	155
26	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2755-2769.	3.0	148
27	A Novel Hypoxia-Inducible Factor~Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 861-871.	2.1	139
28	Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	139
29	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017, 135, 1273-1275.	1.6	133
30	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	1.6	127
31	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	1.1	118
32	Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. <i>British Journal of Anaesthesia</i> , 2018, 120, 645-656.	1.5	115
33	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. <i>Stroke</i> , 2017, 48, 1218-1225.	1.0	112
34	Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease• Results From EMPA-REG OUTCOME<sup>®</sup>. <i>Circulation Journal</i> , 2017, 81, 227-234.	0.7	110
35	Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure. <i>Circulation: Heart Failure</i> , 2008, 1, 9-16.	1.6	105
36	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017, 7, e017157.	0.8	92

#	ARTICLE	IF	CITATIONS
37	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019, 21, 921-929.	2.9	86
38	Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events. <i>Stroke</i> , 2016, 47, 2075-2082.	1.0	83
39	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	1.1	80
40	Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function. <i>Journal of Cardiac Failure</i> , 2010, 16, 25-35.	0.7	76
41	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.	1.8	76
42	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S12-20.	0.9	74
43	Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. <i>International Journal of Cardiology</i> , 2016, 223, 543-547.	0.8	71
44	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 787-798.	1.6	60
45	Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. <i>Clinical Cardiology</i> , 2016, 39, 345-346.	0.7	53
46	Alpha-protein kinase 3 (<i>ALPK3</i>) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2021, 42, 3063-3073.	1.0	51
47	Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®. <i>Diabetologia</i> , 2018, 61, 1522-1527.	2.9	49
48	Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin. <i>Stroke</i> , 2014, 45, 2372-2378.	1.0	46
49	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. <i>American Heart Journal</i> , 2019, 213, 35-46.	1.2	45
50	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD-AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	44
51	The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population. <i>Cardiology</i> , 2008, 110, 271-282.	0.6	39
52	Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population. <i>Heart and Vessels</i> , 2010, 25, 229-236.	0.5	36
53	Impact of gender on event rates at 1-year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017, 7, e014579.	0.8	30
54	Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2780-2782.	1.2	30

#	ARTICLE	IF	CITATIONS
55	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	1.0	28
56	Evolving quality standards for large-scale registries: the GARFIELD-AF experience. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 3, qcw058.	1.8	27
57	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019, 4, 526.	3.0	26
58	Chronic Thromboembolic Pulmonary Hypertension. <i>Deutsches A&#x0308;rzteblatt International</i> , 2014, 111, 856-62.	0.6	24
59	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. <i>Clinical Cardiology</i> , 2019, 42, 498-505.	0.7	24
60	Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AFâ€TIMI 48 Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	21
61	Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 437-443.	1.0	19
62	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.2	16
63	Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. <i>Acta Cardiologica</i> , 2019, 74, 309-318.	0.3	16
64	Rationale, design, and results from RENO-DEFEND 1: A randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. <i>American Heart Journal</i> , 2011, 161, 1012-1023.e3.	1.2	15
65	Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018, 4, 27-35.	1.8	15
66	Advanced age, low left atrial appendage velocity, and Factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 192-199.	1.0	14
67	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. <i>British Journal of Haematology</i> , 2016, 174, 610-623.	1.2	13
68	Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japanâ€â€ Insights From GARFIELD-AF â€. <i>Circulation Journal</i> , 2018, 83, 67-74.	0.7	12
69	An intuitive risk factors search algorithm: usage of the Bayesian network technique in personalized medicine. <i>Journal of Applied Statistics</i> , 2015, 42, 71-87.	0.6	9
70	Circulating miR-499a-5p Is a Potential Biomarker of MYH7â€Associated Hypertrophic Cardiomyopathy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3791.	1.8	9
71	Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). <i>Terapevticheskii Arkhiv</i> , 2022, 94, 584-595.	0.2	9
72	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019, 132, 1431-1440.e7.	0.6	8

#	ARTICLE	IF	CITATIONS
73	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. JACC: Cardiovascular Interventions, 2019, 12, 2331-2341.	1.1	8
74	CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients. Pharmacogenomics Journal, 2020, 20, 687-694.	0.9	8
75	Bleeding risk factors in patients with acute coronary syndrome: data from observational studies ORACUL II. Russian Journal of Cardiology, 2019, 24, 7-16.	0.4	8
76	The use of optimal partitionings for multiparameter data analysis in clinical trials. Mathematical Biology and Bioinformatics, 2016, 11, 46-63.	0.1	8
77	Targeted sequencing in patients with clinically diagnosed hereditary lipid metabolism disorder and acute coronary syndrome. Bulletin of Russian State Medical University, 2018, , 80-86.	0.3	7
78	Title is missing!. Molecular Biology, 2003, 37, 52-55.	0.4	6
79	The polymorphisms G(â~174)C in IL6 gene and G(â~1082)A in IL10 gene are associated with poor outcomes in patients with acute coronary syndrome. Molecular Biology, 2010, 44, 741-747.	0.4	4
80	RESULTS OF MULTICENTER MONITORING OF HEMOSTASIS PARAMETERS IN PATIENTS WITH COVID-19. Pediatriia, 2020, 99, 62-73.	0.1	4
81	Association of the G7831A Polymorphism of the ACE Gene with Coronary Heart Disease in Muscovites. Molecular Biology, 2003, 37, 49-51.	0.4	3
82	Association of the polymorphic markers G(â~455)A in the FGB gene and C(â~1654)T in the PROC gene with hereditary predisposition to unfavourable outcome in patients with history of acute coronary syndrome. Molecular Biology, 2010, 44, 541-545.	0.4	3
83	Screening of familial hypercholesterolemia among patients in age under 40 years old exposed by duplex scanning of carotid arteries, by the local registry data. Terapevticheskii Arkhiv, 2018, 90, 37-41.	0.2	3
84	Inherited thrombophilia and venous thromboembolism: testing rules in clinical practice. Russian Journal of Cardiology, 0, 25, 4024.	0.4	3
85	Late Silent Stent Abscess. Cardiology, 2015, 132, 65-67.	0.6	2
86	Place of Prasugrel, P2Y12 receptor antagonist, in an early invasive treatment of patients with acute coronary syndrome (according to the results of multicenter randomized controlled trial ISAR-REACT) Tj ETQq0 0 0 rgt /Overlck 10 Tf 5		
87	PRIMARY (GENETICALLY DETERMINED) DILATION CARDIOMYOPATHY IN A PATIENT WITH NOVEL MUTATION OF LAMIN GENE: CLINICAL AND MORPHOLOGICAL MANAGEMENT. Cardiovascular Therapy and Prevention (Russian Federation), 2017, 16, 76-82.	0.4	2
88	Contribution of electrocardiography to the diagnosis of cardiomyopathies and athletic heart syndrome. Russian Journal of Cardiology, 0, 25, 4023.	0.4	2
89	Title is missing!. Russian Journal of Genetics, 2000, 36, 1440-1444.	0.2	1
90	Association of Polymorphic Marker A1/A2 of Gene ITGB3 with Coronary Artery Disease and Myocardial Infarction. Russian Journal of Genetics, 2004, 40, 1156-1158.	0.2	1

#	ARTICLE	IF	CITATIONS
91	Association of GNB3 gene C825T polymorphism with coronary heart disease. Russian Journal of Genetics, 2007, 43, 937-941.	0.2	1
92	Polymorphic markers Ala455Val of the THBD gene and Arg353Gln of the F7 gene and genetic association with unfavorable outcomes of coronary atherosclerosis in patients with a history of acute ischemic heart disease. Russian Journal of Genetics, 2011, 47, 1234-1239.	0.2	1
93	Using the ORACLE Risk Score to Assess Hemorrhagic Risk in Patients with Acute Coronary Syndrome and Atrial Fibrillation. Rational Pharmacotherapy in Cardiology, 2021, 17, 11-15.	0.3	1
94	Risk Stratification after an Acute Coronary Syndrome: Significance of Antithrombotic Therapy. Journal of Clinical Medicine, 2021, 10, 1572.	1.0	1
95	Biomarkers in Heart Failure: Apelin Level Is not Associated With Presence and Severity of the Disease. Kardiologiya, 2015, 2_2015, 37-41.	0.3	1
96	GENETIC POLYMORPHISM OF INFLAMMATORY FACTORS IS ASSOCIATED WITH THROMBOEMBOLIC COMPLICATIONS OF ATRIAL FIBRILLATION. Russian Journal of Cardiology, 2015, , 35.	0.4	1
97	GENETIC POLYMORPHISM OF THE INFLAMMATORY CYTOKINE GENES AND ARTERIAL WALL PROPERTIES IN HYPERTENSIVE PATIENTS. Arterial Hypertension (Russian Federation), 2017, 23, 103-111.	0.1	1
98	Family History of Cardiovascular Disease in Patients With Early Development of Acute Coronary Syndrome. Kardiologiya, 2018, 17, 12-17.	0.3	1
99	GENETIC MARKERS OF MYOCARDIAL FIBROSIS: OPPORTUNITY TO PREDICT ADVERSE OUTCOMES IN AORTIC STENOSIS. Russian Journal of Cardiology, 2018, , 32-38.	0.4	1
100	Polymorphism of TNF gene in acute coronary syndrome patients: data from the registries ORACLE I and ORACLE II. Russian Journal of Cardiology, 2018, , 22-27.	0.4	1
101	Molecular cardiology: from decoding the genetic nature and mechanisms of the diseases development to the introduction into the clinic. Terapevticheskii Arkhiv, 2022, 94, 463-466.	0.2	1
102	Anticoagulant properties of the endothelium studied by the standard venous occlusion test. Bulletin of Experimental Biology and Medicine, 1992, 114, 1804-1808.	0.3	0
103	Association of Polymorphic Marker G(“455)A of Gene FGB with Coronary Artery Disease. Russian Journal of Genetics, 2004, 40, 1159-1162.	0.2	0
104	W03-P-008 Genetic basis of inherited predisposition to coronary artery disease. Atherosclerosis Supplements, 2005, 6, 14.	1.2	0
105	Mo-P6:455 Genetic predisposition to unfavourable outcomes in patients with unstable angina. Atherosclerosis Supplements, 2006, 7, 146.	1.2	0
106	THE MODERN ASPECTS OF CLOPIDOGREL USE. Rational Pharmacotherapy in Cardiology, 2010, 6, 185-191.	0.3	0
107	MS216 IL6 AND IL10 GENES ARE ASSOCIATED WITH UNFAVOURABLE OUTCOMES IN PATIENTS WITH ACUTE CORONARY SYNDROME. Atherosclerosis Supplements, 2010, 11, 153.	1.2	0
108	MS217 ASSOCIATION OF THE CHOLESTEROL ESTER TRANSFER PROTEIN GENE (CETP) WITH CORONARY ARTERY DISEASE. Atherosclerosis Supplements, 2010, 11, 153.	1.2	0

#	ARTICLE	IF	CITATIONS
109	634 GENDER DEPENDENT ASSOCIATION BETWEEN KIF6 POLYMORPHISM AND RISK OF UNFAVORABLE OUTCOME IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME. <i>Atherosclerosis Supplements</i> , 2011, 12, 133-134.	1.2	0
110	639 POLYMORPHIC MARKERS OF THBD AND PROC GENES AND GENETIC PREDISPOSITION TO UNFAVOURABLE OUTCOMES IN PATIENTS AFTER ACUTE CORONARY SYNDROME. <i>Atherosclerosis Supplements</i> , 2011, 12, 134-135.	1.2	0
111	WARFARIN IN PATIENTS WITH CARDIOEMBOLIC STROKE. <i>Rational Pharmacotherapy in Cardiology</i> , 2012, 8, 581-586.	0.3	0
112	Multiple coronary fistulae into left ventricle as a rare cause of myocardial ischemia. <i>Atherosclerosis</i> , 2016, 252, e19-e20.	0.4	0
113	[PP.07.21] PARC GENE POLYMORPHISM IS ASSOCIATED THE DEVELOPMENT OF LEFT VENTRICULAR HYPERTROPHY IN ARTERIAL HYPERTENSION. <i>Journal of Hypertension</i> , 2016, 34, e159.	0.3	0
114	[PP.30.09] KIF6 GENE POLYMORPHISM IS ASSOCIATED WITH ARTERIAL RESISTANCE AND ATHEROSCLEROSIS IN PATIENTS WITH HYPERTENSION. <i>Journal of Hypertension</i> , 2017, 35, e333.	0.3	0
115	IL-10 GENE POLYMORPHISM AND STROKE RISK IN PATIENTS WITH CORONARY ARTERY DISEASE. <i>Journal of Hypertension</i> , 2018, 36, e217.	0.3	0
116	Polymorphism of ANXA2 gene may accelerate vulnerability and calcinosis in patients with coronary atherosclerosis. <i>Atherosclerosis</i> , 2018, 275, e102.	0.4	0
117	VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY AND RISK OF ALL-CAUSE DEATH. <i>Journal of Hypertension</i> , 2019, 37, e195.	0.3	0
118	Pitavastatin: focus on safety and drug interactions. <i>Cardiosomatics</i> , 2021, 12, 48-53.	0.2	0
119	Changes in plasma sphingolipid levels against the background of lipid-lowering therapy in patients with premature atherosclerosis. <i>Bulletin of Russian State Medical University</i> , 2021, , .	0.3	0
120	Visit-to-visit blood pressure variability in patients after acute coronary syndrome. <i>Arterial Hypertension (Russian Federation)</i> , 2021, 27, 206-215.	0.1	0
121	ASSOCIATION OF THE POLYMORPHIC MARKERS OF MTHFR, EDN1, CYP11B2, PPARA AND PPARG2 GENES WITH THE SEVERITY OF ESSENTIAL HYPERTENSION. <i>Journal of Hypertension</i> , 2004, 22, S342.	0.3	0
122	Chronic Thromboembolic Pulmonary Hypertension. , 2009, , 359-378.		0
123	PECULIAR PROPERTIES OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION. IS IT POSSIBLE TO DO THE TREATMENT SAFE?. <i>Rational Pharmacotherapy in Cardiology</i> , 2011, 7, 219-226.	0.3	0
124	Current Aspects of Fibrinolysis. <i>Kardiologiya</i> , 2014, 11_2014, 39-44.	0.3	0
125	MOLECULAR-GENETIC FACTORS, ASSOCIATED WITH AORTIC STENOSIS DEVELOPMENT. <i>Russian Journal of Cardiology</i> , 2015, , 99.	0.4	0
126	THE REVOLUTION, WE HAVE ALMOST OVERSLEPT. <i>Russian Journal of Cardiology</i> , 2015, , 7.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Possibilities of molecular biopsy in differential diagnosis of pulmonary arterial hypertension: case description and literature review. Medical News of North Caucasus, 2018, 13, .	0.0	0
128	Risk of Stroke After Exacerbation of Ischemic Heart Disease: Data of 3â€“Years Follow-up. Kardiologiya, 2018, 17, 14-22.	0.3	0
129	Psychosomatic Disorders in Patients with Pulmonary Hypertension: Impact on Treatment Adherence. Psychiatry, 2019, 17, 6-16.	0.2	0
130	A clinical case of hypertrophic cardiomyopathy and family hyperlipidemia. Journal of Clinical Practice, 2019, 10, 97-101.	0.2	0
131	Lipidome features in patients with different probability of family hypercholesterolemia. Bulletin of Russian State Medical University, 2019, , 84-91.	0.3	0
132	Bleeding risk scales in patients with acute coronary syndrome: place of the ORACUL scale. Cardiovascular Therapy and Prevention (Russian Federation), 2020, 19, 2333.	0.4	0
133	Prevalence of hereditary factors in different age groups in patients with acute coronary syndrome. Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR, 2021, 27, 281-290.	0.1	0